Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism: Is It a Ketamine-Specific Effect?
To the Editor: I was delighted to read the article by Williams and colleagues (1) that made an important and intriguing contribution to the field. In the article, published in the December 2018 issue of the Journal, the authors show that 50 mg of naltrexone that saturates both mu and kappa opioid receptors taken 45 minutes before intravenous injection of ketamine attenuated the acute effect of ketamine. The authors’ conclusion was that naltrexone can act either as an antidepressant or as a “mood neutral” compound. In this study, patients were taking selective serotonin reuptake inhibitors (SSRIs) or other antidepressants along with naltrexone or placebo and intravenous ketamine. Because all patients received ketamine, the effect of adding naltrexone without ketamine was not tested. Specifically, the risk of naltrexone exacerbating symptoms in this population was ignored. Studies concerning the combination of antidepressants and naltrexone in a population of abstinent alcoholic-depressive patients who were already taking naltrexone show that the addition of SSRIs had no additional effect (2, 3). It has been claimed that one of the main side effects of naltrexone in this population is depression (4, 5).
The effect of naltrexone on mood in a population without a history of substance abuse is not fully established. Low-dose naltrexone as an add-on treatment may improve depression in patients with fibromyalgia (6, 7), while a higher dose of naltrexone in combination with SSRIs might exacerbate depressive symptoms (8).
Nevertheless, this work raises many interesting questions concerning the involvement of the opiate system in the treatment of depression. It would be interesting to further investigate whether opiate antagonists can attenuate the effect of other antidepressant treatments (e.g., ECT).
1 : Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018; 175:1205–1215Link, Google Scholar
2 : A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2015; 35:143–149Crossref, Medline, Google Scholar
3 : Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006; 26:13–20Crossref, Medline, Google Scholar
4 : Accounting for the uncounted: physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug Alcohol Depend 2018; 192:264–270Crossref, Medline, Google Scholar
5 : Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci 2006; 31:38–45Medline, Google Scholar
6 : The use and utility of low-dose naltrexone capsules for patients with fibromyalgia. Int J Pharm Compd 2018; 22:252–256Medline, Google Scholar
7 : Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord 2017; 208:6–14Crossref, Medline, Google Scholar
8 : Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008; 18:455–461Crossref, Medline, Google Scholar